Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

752
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
752
Management of Insomnia01:19

Management of Insomnia

375
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
375
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

318
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
318
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

322
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
322
Narcolepsy01:07

Narcolepsy

286
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
286
Sleep-Wake Cycles01:24

Sleep-Wake Cycles

2.2K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and  rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GLRB-Related Hyperekplexia Presenting as Neonatal Seizure-Like Events.

Journal of paediatrics and child health·2026
Same author

Classic psychedelics and personality: An updated systematic review.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Placebo Effect in Levodopa-Induced Dyskinesia: A Systematic Review and Meta-Analysis.

Movement disorders clinical practice·2026
Same author

Levodopa-Induced dyskinesia in Latin America: Prevalence and associated clinical factors in the LARGE-PD cohort.

Journal of Parkinson's disease·2026
Same author

Early-life exposure to Cannabidiol: Safety assessment of a chronic exposure in Caenorhabditis elegans.

Toxicology and applied pharmacology·2026
Same author

Effects of ayahuasca on neuropsychological performance and social cognition: A systematic review.

Journal of psychopharmacology (Oxford, England)·2026

Related Experiment Video

Updated: Nov 11, 2025

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

2.7K

Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder.

Carlos M O de Almeida1, Manuelina M C Brito2, Nayanne B Bosaipo2

  • 1School of Health Sciences, State University of Amazonas, Manaus, Amazon, Brazil.

Movement Disorders : Official Journal of the Movement Disorder Society
|March 23, 2021
PubMed
Summary

Cannabidiol (CBD) did not reduce REM sleep behaviour disorder (RBD) in Parkinson's disease (PD) patients. However, a transient improvement in sleep satisfaction was observed with a 300mg dose of CBD.

Keywords:
sleep; cannabidiol; rapid eye movement sleep behavioral disorder; Parkinson's disease

More Related Videos

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
06:23

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice

Published on: September 22, 2020

5.7K
Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

10.1K

Related Experiment Videos

Last Updated: Nov 11, 2025

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

2.7K
A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
06:23

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice

Published on: September 22, 2020

5.7K
Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

10.1K

Area of Science:

  • Neurology
  • Sleep Medicine
  • Pharmacology

Background:

  • REM sleep behaviour disorder (RBD) is a frequent non-motor symptom in Parkinson's disease (PD).
  • Cannabidiol (CBD), a non-psychoactive cannabis compound, is explored for RBD treatment.
  • Investigating CBD's potential in managing RBD in PD patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of CBD in treating RBD in Parkinson's disease patients.
  • Assessing CBD's impact on primary outcomes like RBD frequency and clinical severity ratings.
  • Examining secondary outcomes, including sleep satisfaction.

Main Methods:

  • Phase II/III, double-blind, placebo-controlled clinical trial.
  • 33 patients with RBD and PD were randomized to CBD (75-300mg) or placebo.
  • 14-week follow-up period with primary outcome assessment.

Main Results:

  • No significant difference between CBD and placebo for primary outcomes (RBD frequency, CGI-I, CGI-S).
  • A significant improvement in average sleep satisfaction was noted in the CBD group from week 4 to 8 (P = 0.049, P = 0.038).
  • No reduction in RBD manifestations was observed with CBD as an adjunct therapy.

Conclusions:

  • CBD did not demonstrate efficacy in reducing RBD symptoms in Parkinson's disease patients.
  • A transient improvement in sleep satisfaction was observed at a 300mg CBD dose.
  • Further research may explore CBD's specific effects on sleep quality in PD.